"uuid:ID","name","label","instanceType","id","description","rationale"
"b3cabb8a-49cd-45a5-b057-cf0e8bef71bf","Study Design 1","","StudyDesign","StudyDesign_1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
